Last Updated: November 16, 2026

RYBREVANT Drug Profile

« Back to Dashboard


Summary for Tradename: RYBREVANT
High Confidence Patents:3
Applicants:1
BLAs:2
Recent Clinical Trials: See clinical trials for RYBREVANT
Recent Clinical Trials for RYBREVANT

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Janssen Research & Development, LLCPhase 1/Phase 2
Fate TherapeuticsPhase 1

See all RYBREVANT clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. DrugPatentWatch analysis and company disclosures
  4. These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for RYBREVANT Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for RYBREVANT Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Janssen Biotech, Inc. RYBREVANT amivantamab-vmjw Injection 761210 ⤷  Start Trial 2034-05-21 DrugPatentWatch analysis and company disclosures
Janssen Biotech, Inc. RYBREVANT amivantamab-vmjw Injection 761210 ⤷  Start Trial 2033-11-21 DrugPatentWatch analysis and company disclosures
Janssen Biotech, Inc. RYBREVANT amivantamab-vmjw Injection 761210 ⤷  Start Trial 2036-12-21 DrugPatentWatch analysis and company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for RYBREVANT Derived from Patent Text Search

No patents found based on company disclosures

Supplementary Protection Certificates for RYBREVANT

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
PA2022507,C2922872 Lithuania ⤷  Start Trial PRODUCT NAME: AMIVANTAMABAS; REGISTRATION NO/DATE: EU/1/21/1594 20211209
2290016-1 Sweden ⤷  Start Trial PRODUCT NAME: AMIVANTAMAB; REG. NO/DATE: EU/1/21/1594 20211210
202240014 Slovenia ⤷  Start Trial PRODUCT NAME: AMIVANTAMAB; NATIONAL AUTHORISATION NUMBER: EU/1/21/1594; DATE OF NATIONAL AUTHORISATION: 20211209; AUTHORITY FOR NATIONAL AUTHORISATION: EU
LUC00257 Luxembourg ⤷  Start Trial PRODUCT NAME: AMIVANTAMAB; AUTHORISATION NUMBER AND DATE: EU/1/21/1594 20211210
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

RYBREVANT Market Dynamics, Financial Trajectory, Patent Position, and Generic Risk

Last updated: October 15, 2026

Rybrevant, the brand name for amivantamab-vmjw, has moved from a niche treatment for EGFR exon 20 insertion non-small-cell lung cancer into a broader EGFR-directed franchise. Johnson & Johnson’s reported Rybrevant sales increased from approximately $149 million in 2021 to about $544 million in 2023. Growth is being driven by additional post-platinum use, first-line combinations, and the potential expansion of amivantamab with lazertinib across common EGFR-mutated lung cancer.

The principal commercial risk is eventual competition from EGFR tyrosine kinase inhibitors, antibody combinations, and biosimilars after biologic exclusivity and patent barriers weaken. The principal upside is the conversion of amivantamab from a biomarker-specific product into a backbone therapy for several EGFR-mutated disease settings.

What is Rybrevant and which patients does it treat?

Rybrevant is an intravenous bispecific antibody targeting EGFR and MET. Johnson & Johnson markets it through Janssen Biotech. Genmab developed the antibody using its DuoBody platform under a collaboration with Janssen.

The product was initially approved for adults with locally advanced or metastatic NSCLC whose tumors have EGFR exon 20 insertion mutations and whose disease progressed on or after platinum-based chemotherapy. The FDA granted accelerated approval in May 2021 based on response-rate and duration-of-response data from the CHRYSALIS study. [1]

The addressable population expanded through later approvals:

Market segment Rybrevant role Commercial effect
EGFR exon 20 insertion NSCLC after platinum chemotherapy Initial approved use Established the product in a genetically defined niche
EGFR exon 20 insertion NSCLC with carboplatin and pemetrexed Earlier-line treatment Increased treatment duration and eligible patient volume
EGFR exon 19 deletion or L858R NSCLC with lazertinib First-line combination strategy Opens a much larger EGFR-mutated market
EGFR-mutated NSCLC after progression on targeted therapy Combination and sequencing opportunity Supports use beyond the initial line of therapy

The exon 20 insertion population is relatively small but has historically lacked effective targeted treatment. The common EGFR mutation population is much larger and is dominated by osimertinib, marketed as Tagrisso by AstraZeneca.

How have Rybrevant sales changed since launch?

Rybrevant sales have grown rapidly from a small launch base.

Fiscal year Reported Rybrevant sales Approximate year-over-year growth
2021 $149 million First commercial year
2022 $379 million 154%
2023 $544 million 44%

Sources: Johnson & Johnson annual reports and fourth-quarter earnings disclosures. [2-4]

The sales trajectory reflects four commercial phases:

  1. 2021 launch: Initial uptake was limited by the small exon 20 insertion population, intravenous administration, diagnostic testing, and the requirement for prior platinum therapy.
  2. 2022 scale-up: Greater oncologist awareness and improved identification of EGFR exon 20 insertions increased adoption.
  3. 2023 expansion: Broader use after platinum therapy and the addition of chemotherapy combinations increased treatment exposure.
  4. 2024 onward: The combination strategy with lazertinib creates the largest potential growth step because it positions Rybrevant in first-line common EGFR-mutated NSCLC.

Reported sales are product sales, not necessarily net sales by indication. Johnson & Johnson does not publicly separate revenue by mutation, line of therapy, geography, or combination regimen.

What are the main drivers of Rybrevant revenue growth?

First-line expansion

The exon 20 insertion indication alone limits peak revenue because the mutation represents a small proportion of EGFR-mutated NSCLC. First-line use in common EGFR mutations changes the market size materially.

The MARIPOSA program evaluated lazertinib with amivantamab against osimertinib in previously untreated EGFR-mutated advanced NSCLC. The combination produced a progression-free survival advantage over osimertinib in the reported Phase 3 results. [5]

A first-line combination can generate higher annual revenue per patient than later-line monotherapy because:

  • treatment begins at diagnosis of advanced disease;
  • patients remain on therapy longer if disease is controlled;
  • amivantamab is paired with another branded product;
  • treatment can extend into subsequent lines through sequencing;
  • the eligible population includes EGFR exon 19 deletion and L858R mutations, not only exon 20 insertions.

The commercial constraint is administration burden. Rybrevant requires intravenous infusion, with intensive early dosing and infusion-related reaction management. Lazertinib is oral. Tagrisso is also oral, which gives AstraZeneca an important convenience advantage.

Combination economics

The commercial model increasingly depends on selling amivantamab as part of a regimen rather than as a narrowly indicated antibody.

The key combinations are:

  • amivantamab plus carboplatin and pemetrexed for EGFR exon 20 insertion disease in earlier treatment;
  • amivantamab plus lazertinib for common EGFR-mutated disease;
  • potential later-line use after progression on EGFR tyrosine kinase inhibitors.

Combination use can increase revenue per treated patient, but reimbursement and regimen complexity may limit uptake. Infusion-center capacity is another practical constraint.

Greater mutation testing

Rybrevant demand depends on molecular diagnosis. Wider use of next-generation sequencing and liquid biopsy should increase detection of actionable EGFR alterations. Exon 20 insertion mutations can be missed by some testing platforms, creating a commercial opportunity for broader genomic testing.

Testing rates remain a market bottleneck in community oncology, especially where tissue is limited or turnaround times delay treatment decisions.

What is the FDA regulatory status of Rybrevant?

Rybrevant was approved under the FDA accelerated-approval pathway in May 2021 for EGFR exon 20 insertion NSCLC after platinum chemotherapy. [1]

The FDA later expanded the label to include combination treatment with carboplatin and pemetrexed for EGFR exon 20 insertion NSCLC. The approval was supported by the PAPILLON study, which showed improved progression-free outcomes for amivantamab plus chemotherapy compared with chemotherapy alone. [6]

In August 2024, the FDA approved lazertinib in combination with amivantamab for locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitutions. The approval was based on MARIPOSA. [7]

This approval materially changes the franchise profile. The product is no longer dependent solely on the rare exon 20 insertion segment.

How does Rybrevant compare with competing EGFR drugs?

Product Company Modality Core EGFR market Principal competitive advantage
Rybrevant Johnson & Johnson IV EGFR/MET bispecific antibody Exon 20 insertion; common EGFR mutations with lazertinib Activity across mutation settings and antibody-based mechanism
Tagrisso AstraZeneca Oral EGFR TKI Broad first-line EGFR-mutated NSCLC Established standard of care and oral convenience
Exkivity Takeda Oral EGFR TKI EGFR exon 20 insertion Oral administration, but commercial and regulatory withdrawal reduced competitive pressure
Lazcluze Johnson & Johnson Oral third-generation EGFR TKI Used with Rybrevant in common EGFR mutations Complements Rybrevant in first-line combination therapy
Chemotherapy Multiple companies Cytotoxic drugs Broad NSCLC population Low cost and established reimbursement

Tagrisso remains the central benchmark in common EGFR-mutated NSCLC. Rybrevant and lazertinib must justify additional administration complexity, adverse events, and cost through superior efficacy or duration of disease control.

For exon 20 insertion disease, Rybrevant has a stronger position because it is supported by a dedicated development program and is integrated with chemotherapy. Exkivity was withdrawn from the U.S. market in 2024 after Takeda reported that confirmatory data did not meet the required endpoint. [8]

What is the financial trajectory and revenue opportunity?

The near-term trajectory is a shift from sub-$1 billion product revenue toward potential multibillion-dollar franchise revenue if first-line combination adoption is strong.

A directional commercial framework is:

Scenario Commercial assumptions Revenue implication
Low case Continued concentration in exon 20 insertion disease; limited first-line adoption Gradual growth with an eventual plateau
Base case Durable uptake in exon 20 insertion disease and moderate use with lazertinib Continued high growth through the first-line launch cycle
High case Broad substitution or use alongside osimertinib in common EGFR-mutated NSCLC Multibillion-dollar annual sales potential

The high case requires several conditions:

  • positive and durable clinical differentiation versus osimertinib;
  • guideline inclusion and payer coverage;
  • manageable infusion reactions and skin toxicities;
  • adequate infusion-center capacity;
  • adoption by community oncologists;
  • successful commercial execution for lazertinib;
  • no major safety signal in long-term combination use.

Johnson & Johnson’s broader oncology portfolio reduces the commercial burden of selling the combination. The company already has relationships with thoracic oncologists, diagnostic laboratories, and oncology practices.

What patents protect Rybrevant?

Rybrevant is a biologic, so its exclusivity profile differs from that of a conventional small-molecule drug.

The main protection layers are:

  1. Biologic regulatory exclusivity: The FDA generally cannot approve a biosimilar referencing a biologic until 12 years after the reference product’s first licensure under the Biologics Price Competition and Innovation Act. Rybrevant received initial U.S. licensure in May 2021, implying regulatory protection through approximately May 2033, subject to statutory treatment of the product and any pediatric extension. [1,9]

  2. Composition-of-matter and antibody patents: These can cover the amivantamab antibody, specific variable-region sequences, binding characteristics, epitope interactions, and antibody formats.

  3. Bispecific-platform patents: Genmab’s DuoBody technology and related platform rights may protect production and assembly methods.

  4. Method-of-use patents: These may cover treatment of EGFR mutations, MET-expressing tumors, combination regimens, dosing schedules, or disease progression settings.

  5. Formulation and manufacturing patents: These can protect concentration, stability, cell-culture processes, purification, and commercial-scale production.

The strongest commercial protection is likely to come from the combination of biologic exclusivity, antibody patents, manufacturing complexity, and method-of-use claims. A biosimilar entrant would need to establish comparability for a complex bispecific antibody and address multiple patent families.

When does Rybrevant lose exclusivity?

The practical U.S. biosimilar timing floor is around 2033, based on the May 2021 first licensure date. Patent expiry may extend beyond that date, depending on the enforceability and term of relevant U.S. patents.

Patent-term adjustment, patent-term extension, pediatric exclusivity, terminal disclaimers, and claim scope can change the effective barrier. Because biologic patent portfolios are not equivalent to the single compound patent model used for small molecules, no single expiration date captures the full Rybrevant exclusivity risk.

The likely sequence is:

Period Exclusivity position
2021-2024 Originator dominance; no biosimilar approval pathway available
2025-2032 Commercial expansion and possible patent litigation around follow-on products
Around 2033 Earliest general U.S. biosimilar approval window based on statutory exclusivity
Post-2033 Biosimilar and patent-based entry risk increases
Beyond 2033 Manufacturing, interchangeability, clinical confidence, and payer contracting become decisive

Are there Paragraph IV challenges to Rybrevant?

Paragraph IV litigation is primarily a small-molecule Hatch-Waxman mechanism. Rybrevant is regulated as a biologic under a BLA, so a biosimilar applicant would generally use the BPCIA patent-exchange and litigation framework rather than filing a conventional Paragraph IV certification.

Publicly disclosed Rybrevant market risk is therefore more likely to arise from:

  • biosimilar patent-dispute procedures;
  • invalidity or non-infringement challenges to antibody patents;
  • challenges to method-of-use or manufacturing patents;
  • competing clinical regimens;
  • payer-driven substitution after biosimilar approval.

No major publicly established Rybrevant biosimilar litigation has defined the product’s U.S. market as of the 2024 regulatory period covered here.

How strong is the Rybrevant patent estate?

The estate is commercially strong but technically complex.

Strengths

  • The product is a proprietary bispecific antibody rather than a simple small molecule.
  • Manufacturing and analytical characterization create meaningful entry barriers.
  • The antibody can be protected through sequence, epitope, functional, and format claims.
  • Multiple clinical indications create opportunities for method-of-use protection.
  • The DuoBody development platform adds technical and licensing depth.
  • The 12-year biologic exclusivity period extends beyond the initial patent life of many conventional drugs.

Weaknesses

  • Antibody composition claims can be challenged through sequence and prior-art arguments.
  • Method-of-use claims may be narrower than composition claims.
  • Combination claims may be vulnerable if the regimen is considered obvious or insufficiently differentiated.
  • Biosimilar developers can seek approval for a narrower indication while litigating only selected patents.
  • IV administration and infusion reactions create competitive pressure independent of patent strength.

Patent quality will depend on claim breadth, prosecution history, written-description support, inventorship, and the specific patent families listed or asserted by Johnson & Johnson and Genmab.

What licensing deals affect Rybrevant economics?

Genmab and Janssen entered a collaboration in 2012 covering Genmab’s DuoBody technology and development of antibody therapeutics. Janssen obtained commercial rights to products developed under the collaboration, while Genmab retained economic participation through milestone payments and royalties. [10]

The agreement matters financially because Rybrevant revenue is shared through collaboration economics rather than being retained entirely by Johnson & Johnson. Genmab has reported royalty and milestone income tied to amivantamab and related products.

The deal also gives Johnson & Johnson access to a broader antibody platform. This creates strategic value beyond Rybrevant sales, including possible follow-on bispecific programs.

What manufacturing and IP barriers affect generic or biosimilar entry?

Rybrevant manufacturing is a major barrier to rapid competition. A biosimilar developer must demonstrate:

  • high similarity to the reference antibody;
  • consistent binding to EGFR and MET;
  • comparable pharmacokinetics;
  • comparable immunogenicity;
  • robust large-scale cell-culture production;
  • reliable purification and fill-finish operations;
  • clinical and analytical support for the proposed indications.

The product’s IV formulation and infusion procedures also create operational barriers. A biosimilar can be approved without being identical in every manufacturing detail, but the sponsor must establish that differences do not produce clinically meaningful effects.

Manufacturing barriers will not prevent entry indefinitely. They can delay launch, raise development costs, and reduce the number of credible competitors.

What litigation and settlement risks affect Rybrevant?

As of the 2024 regulatory period, no settlement agreement comparable to major small-molecule generic settlements has defined Rybrevant’s U.S. market. Future disputes are more likely to involve biosimilar applicants, antibody composition patents, manufacturing claims, and indications for combination therapy.

Potential settlement outcomes include:

  • delayed biosimilar entry before statutory exclusivity expires;
  • launch on a subset of indications;
  • licensing of selected patent claims;
  • royalty-bearing entry;
  • carve-outs for patented methods of treatment;
  • competition limited to non-protected formulations or indications.

A settlement could preserve meaningful originator pricing even after biosimilar approval if the most valuable first-line indications remain protected.

What is the outlook for Rybrevant’s competitive position?

Rybrevant has a two-part commercial strategy.

The first is defensive: retain leadership in EGFR exon 20 insertion NSCLC through combination therapy and earlier-line treatment.

The second is expansive: use lazertinib to compete in the much larger common EGFR-mutated NSCLC market dominated by Tagrisso.

The main commercial test is whether the added clinical benefit of amivantamab plus lazertinib offsets the burden of IV treatment. If oncologists view the combination as a clear efficacy upgrade, Rybrevant could become a major oncology product. If the benefit is incremental and administration burdensome, use may remain concentrated in selected high-risk patients and later-line settings.

Key Takeaways

  • Rybrevant sales increased from about $149 million in 2021 to $544 million in 2023.
  • The initial exon 20 insertion market established the product but was too small to support the largest revenue opportunity.
  • The commercial upside comes from first-line treatment of common EGFR mutations with lazertinib.
  • Tagrisso is the primary competitive benchmark because it is oral, established, and widely used.
  • Rybrevant received U.S. biologic licensure in May 2021, implying a statutory biosimilar approval floor around May 2033.
  • Biologic exclusivity, antibody patents, manufacturing complexity, and combination-use patents collectively strengthen the franchise.
  • Paragraph IV is not the principal challenge mechanism because Rybrevant is a biologic; future disputes are more likely to proceed under the BPCIA.
  • The largest execution risks are infusion burden, adverse events, payer controls, diagnostic testing, and failure to demonstrate a compelling advantage over osimertinib.
  • Genmab’s royalty and collaboration economics reduce Johnson & Johnson’s gross economic retention but provide access to the DuoBody platform.
  • Rybrevant’s long-term value depends more on first-line combination adoption than on the original exon 20 insertion indication.

Frequently Asked Questions

What mutation does Rybrevant target?

Rybrevant targets EGFR and MET. Its initial approval covered EGFR exon 20 insertion mutations. Later development expanded to common EGFR mutations, including exon 19 deletions and exon 21 L858R substitutions, when used with lazertinib.

Is Rybrevant a chemotherapy drug?

No. Rybrevant is an intravenous bispecific antibody. It is often administered with chemotherapy in approved regimens, but it is not itself a cytotoxic chemotherapy.

Does Rybrevant have biosimilar competition?

No approved U.S. biosimilar competition was established during the 2024 regulatory period. The earliest general approval window based on the 12-year biologic exclusivity period is approximately 2033.

Who manufactures Rybrevant?

Johnson & Johnson markets Rybrevant through Janssen Biotech. Genmab is the technology and collaboration partner associated with the DuoBody platform and receives economic participation under the companies’ collaboration.

What is the biggest threat to Rybrevant revenue?

The biggest threat is weaker-than-expected adoption of the amivantamab-lazertinib combination against Tagrisso. IV administration, infusion reactions, cost, and the need for clear clinical differentiation may limit use in the broader EGFR-mutated NSCLC market.

References

  1. U.S. Food and Drug Administration. (2021). FDA grants accelerated approval to amivantamab-vmjw for metastatic non-small cell lung cancer. FDA.

  2. Johnson & Johnson. (2022). 2021 annual report. Johnson & Johnson.

  3. Johnson & Johnson. (2023). 2022 annual report. Johnson & Johnson.

  4. Johnson & Johnson. (2024). 2023 annual report. Johnson & Johnson.

  5. Cho, B. C., et al. (2024). Amivantamab plus lazertinib in EGFR-mutated advanced NSCLC. New England Journal of Medicine.

  6. U.S. Food and Drug Administration. (2024). FDA approves amivantamab with chemotherapy for EGFR exon 20 insertion-mutated NSCLC. FDA.

  7. U.S. Food and Drug Administration. (2024). FDA approves lazertinib with amivantamab-vmjw for EGFR-mutated NSCLC. FDA.

  8. Takeda Pharmaceutical Company Limited. (2024). Exkivity market withdrawal announcement. Takeda.

  9. U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009. Patient Protection and Affordable Care Act, §7002.

  10. Genmab A/S. (2024). Annual report 2023. Genmab.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.